Viral load, CD4 cell counts and antibodies: What do we know and what does it all mean? Brian Williams, SACEMA, November 2007.

Slides:



Advertisements
Similar presentations
Modelling the impact of male circumcision on HIV/AIDS in sub-Saharan Africa Brian Williams, SACEMA 14 November 2007.
Advertisements

Phases of HIV/AIDS 1. Infection 2. Window period 3. Seroconversion 4. Asymptomatic period 5. HIV/AIDS - related illness 6. AIDS.
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
April 15 Understanding HIV Treatment and adherence. The African Eye Trust HIV Treatment Information Event By Badru Male&Elijah Amooti.
Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.
The HIV Engagement in Care Cascade Edward Gardner, MD Associate Professor of Medicine Denver Public Health University of Colorado Denver.
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
K. Jean, P. Lissouba, D. Taljaard, R. Rain-Taljaard, B. Singh, J. Bouscaillou, G. Peytavin, R. Sitta, S.G. Mahiane, D. Lewis, A. Puren, B. Auvert Inserm.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Treatment as prevention (TASP) for HIV and HCV: The evidence and modelling Peter Vickerman.
 The Kingdom of Lesotho  landlocked country entirely surrounded by the Republic of South Africa.landlockedRepublic of South Africa  over 30,000 km².
Modelling changes in HIV prevalence among women attending antenatal clinics in Uganda Brian Williams.
Basic Facts on HIV/AIDS By David Schulman. Learning objectives By the end of this presentation you will be able to: Discuss the difference between HIV.
Module 7: Malaria and HIV/AIDS Palliative Care for People Living with HIV/AIDS.
Natural History and Clinical Staging of HIV Training for Medical Officers Day 2 Session 7.
2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
Ending AIDS Past, Present and Yet to Come Brian Williams Newton Institute August 2013 Ask not what public health can do for epidemiology but what epidemiology.
Instructions for using this template. Remember this is Jeopardy, so where I have written “Answer” this is the prompt the students will see, and where.
Summarising Male Circumcision Efficacy: Results of the three randomised clinical trials Neil A Martinson Perinatal HIV Research Unit.
AfterBefore PTH pg/ml PTH pg/ml AfterBefore Case Report 1) Age 53, 17 yrs HIV infection TDF/FTC/EFZ Baseline 25(OH)D.
What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
WHY YOU NEED TO CREATE AN AWARENESS FOR AIDS Click to Continue to Next Page.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Slide 1 of 11 From DA Wohl, MD, at New York, NY: May 03, 2012, IAS-USA. IAS–USA David Alain Wohl, MD Associate Professor of Medicine The University of.
Effects of a Mobile Phone Short Message Service (SMS) on Antiretroviral Treatment Adherence in Kenya (WelTel Kenya1): A Randomized Trial Jesse Coleman.
Late Presentation of HIV Infection James Hand Clinical Nurse Manager for HIV & Hepatitis Research Barts Health NHS Trust.
Cost-effectiveness of male circumcision in reducing the spread of HIV in the general population in sub-Saharan Africa Jim Kahn & Elliot Marseille, UCSF.
HIV/renal studies (CHIC) Baseline renal function as predictor of HIV/renal disease progression –Death, opportunistic infection –Severe chronic kidney disease.
GAP Report 2014 People left behind: People aged 50 years and older Link with the pdf, People aged 50 years and older.
Chapter 54 Chapter 54 HIV and Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Antiretroviral Treatment Monitoring: A Canadian Case Example Antiretroviral Treatment Monitoring: A Canadian Case Example Robert Hogg, PhD BC Centre for.
Washington D.C., USA, July 2012www.aids2012.org Pregnancy and HIV Acquisition Nelly Mugo Kenyatta National Hospital/ University of Washington Hormonal.
HIV-1 dynamics Perelson et.al. Science 271:1582 (1996) Infected CD4 + lymphocytes Uninfected, activated CD4 + lymphocytes HIV-1 t 1/ days t 1/2.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
Strategic Information and the Control of Tuberculosis Brian Williams and Chris Dye TB programme, Monitoring and Evaluation, WHO.
Approaches to estimation of the number of people with undiagnosed HIV infection in a country - based on prevalence surveys - based on reported numbers.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
High-impact interventions. Number of people living with HIV who were not receiving antiretroviral therapy, 2014 and 2015 Source: UNAIDS estimates, 2014.
ARV-Based Prevention: Perspective from Epidemiology & Modelling Tim Hallett Imperial College London.
Outcomes in ART treatment programmes with and without access to routine viral load monitoring Olivia Keiser on behalf of IeDEA Southern Africa
Can early antiretroviral therapy fully restore health? Workshop on Pathogeneses and Management of Long-Term Complications of ART IAS Conference, Rome July.
HIV & AIDS GENERAL AWARENESS. Why should you know about HIV & AIDS ? HIV infection is preventable with correct knowledge and adoption of safe practices.
Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.
HIV in America What’s New in 2012 Christopher Hurt, MD Clinical Assistant Professor NC AIDS Education and Training Center 2012 HIV Update.
Paz Bailey G 1, Sternberg M 1, Puren AJ 2, Markowitz LE 1, Ballard R 1, Delany S 3, Hawkes S 4, Nwanyanwu O 1, Ryan C 1, and Lewis DA 5 1. NCHHSTP, CDC.
Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.
Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
IAS 2014, Melbourne Mechanisms of non-pathogenicity in HIV- Lessons from paediatric infection.
Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.
Problems of HIV Infection in the HAART Era Akihiko Suganuma M.D. Tokyo Metropolitan Komagome Hospital Department of Infectious Diseases.
04/19/ Projected effectiveness of mass HIV vaccination with multi-dose regimens to be tested in South Africa Peter Gilbert Dobromir Dimitrov Christian.
Boston University Slideshow Title Goes Here District Prevalence of Unsuppressed HIV in South African Women: Monitoring Programme Performance and Progress.
Accounting for uncertainty in the timing of seroconversion in combined models for pre- and post-treatment CD4 counts in HIV-patients Oliver Stirrup, Andrew.
How complicated do we want to make this?
Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study  Dr Brian G Williams, PhD, Somya Gupta, MA,
AIDS supplement.
Hiv.
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load by Steven G. Deeks, Christina.
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
(A) Meta-analysis retention: Forest plot of the proportion of HIV-infected adolescents and young adults in South Africa retained in care. (A) Meta-analysis.
Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study  Dr Brian G Williams, PhD, Somya Gupta, MA,
ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: PROGRESS & CHALLENGES IN SOUTH AFRICA YOGAN PILLAY DEPARTMENT OF HEALTH, SOUTH AFRICA IAS, 2014.
Volume 373, Issue 9672, Pages (April 2009)
Flow diagram of literature reviewed for meta-analysis of retention in care and viral suppression for HIV-infected adolescents and young adults in South.
Presentation transcript:

Viral load, CD4 cell counts and antibodies: What do we know and what does it all mean? Brian Williams, SACEMA, November 2007

We have not succeeded in answering all your problems. The answers we have found only serve to raise a whole set of new questions. In some ways we feel that we are as confused as ever but we believe that we are confused on a higher level and about more important things. Notice at the Cambridge University Computer Centre ‘Surgery’, 1970.

Viral load CD4 Antibodies Time The standard model Acute phase ~ weeks Final phase ~ months Interested in the long chronic phase ~ 10 yrs

CD4 cells/  L Virions/mL Orange Farm, South Africa. (Auvert et al. PLOS Medicine, 2005) Viral load and CD4 cell counts

10, CD4 cells/  L Virions/  L Orange Farm, South Africa. (Auvert et al. PLOS Medicine, 2005) Viral load and CD4 cell counts

Virions/μL CD4 slope/  L/year Rodriguez et al. Jama, CD4 cell count decline for different viral loads

Optical density  log(antibody concentration) CD4 cells /  L Antibody concentration and CD4 cell counts ZVITAMBO (Hargrove, pers. comm.)  Up to 2000

Quite solid relationships buried in a vast amount of noise What does the underlying relationship imply? 2. Where does the noise come from? Problem: We have lots of cross-sectional data but little time series data

Viral load/  L Frequency ,000 Orange Farm, South Africa. (Auvert et al. PLOS Medicine 2005) Viral load distribution: Young men in Orange Farm, South Africa

Orange Farm, South Africa. (Auvert et al. PLOS Medicine 2005); Zambia (Kelly et al. Acta Tropica 2002) CD4 cell counts in HIV-positive and HIV-negative people

Optical density i.e. ln(antibody concentration) Frequency Log antibody distribution: Harare

Combine the individual decline with the initial distribution Time (years) CD4 cells/  l Assume that survival is independent of the initial value of the CD4 cell count HIV– Survival CD4

Log(Initial viral load) sets survival CD4 in HIV– CD4 Time Assume that survival is independent of the initial value of the CD4 cell count

Orange Farm, South Africa. (Auvert et al. PLOS Medicine 2005); Zambia (Kelly et al. Acta Tropica 2002) CD4 cell counts in HIV-positive and HIV-negative people

Distribution of CD4 cell count decline

Time years Frequency Orange Farm, South Africa. (Auvert et al. PLOS Medicine 2005) Survival of young men in Orange Farm, South Africa? Survival (yrs) = 42.2 – 6.5  log 10 (VL/  L) Viral load Weibull survival

1. Survival is (almost) independent of initial CD4 cell count 2. Survival is (entirely) determined by log(set-point viral load) 3. Viral load declines exponentially with CD4: 4. Antibody concentration declines exponentially with CD4: So we need to explain why:

Years since infection Proportion surviving Survival against age at HIV seroconversion Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active anti- retroviral therapy A collaborative re-analysis. Cascade Collaboration. Lancet 2001:  1137

Lusaka Gauteng Incidence Prevalence Death

Lusaka Gauteng